Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30685441 | 0.82 | FFAR2 (0.50) | FFAR2KDRCCNE1CDK2 | |
| SCHEMBL24074021 | 0.81 | FFAR2 (0.45) | FFAR2KDR | |
| SCHEMBL30142679 | 0.81 | FFAR2 (0.45) | FFAR2KDR | |
| SCHEMBL4394535 | 0.79 | FFAR2 (0.49) | FFAR2KDR | |
| SCHEMBL15871383 | 0.79 | AOC3 (0.42) | CCNE1CDK2CDK1CDK4CCNE2 | |
| SCHEMBL31282374 | 0.79 | FFAR2 (0.52) | FFAR2KDRCCNE1CDK2CDK1 | |
| SCHEMBL4962455 | 0.77 | MEN1 (0.52) | — | |
| SCHEMBL15941111 | 0.76 | FFAR2 (0.45) | FFAR2 | |
| SCHEMBL15940820 | 0.76 | CA12 (0.46) | FFAR2 | |
| SCHEMBL12562416 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168642-B2 | Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2012-05-01 | — | — | US | disclosed |
| US-20100087448-A1 | Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2010-04-08 | — | — | US | disclosed |
| EP-2039686-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN PREPARATION OF MEDICAMENTS FOR TREATING AND PREVENTING ANTIVIRAL DISEASES | Beijing Molecule Science and Technology Co., Ltd. (CN) | 2009-03-25 | — | — | EP | disclosed |
| US-4324899-A | 2-Amino-5-cyanothiazoles and their preparation | EASTMAN KODAK COMPANY (US) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087448-A1 | Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases | DPYD, HPRT1, DHX15 | FFAR2 4715/4885KDR 4353/4885CCNE1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.